From 1 September 2025, access to KALYDECO (ivacaftor) has been expanded under the Pharmaceutical Benefits Scheme (PBS), making this life-changing treatment available to patients aged one month and older who carry at least one gating mutation in the CFTR gene, as well as those with at least one non-gating mutation shown to be responsive to ivacaftor through clinical and/or in vitro data.
This expansion marks an important step forward in improving treatment options and quality of life for people living with cystic fibrosis.